Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. ELZONRISď (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Additional pipeline candidates include: felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in glioblastoma patients completed), and SL-901 (novel kinase inhibitor; prior abbreviated European Phase 1, IND-enabling studies ongoing). Source
No articles found.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on devel...
Jaguar Health, Inc. is a commercial stage pharm...
argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...
argenx is a clinical-stage biotechnology compan...
Voom has developed a multi-platform wellness program to address both the injuries ...
Voom has developed a multi-platform wellness pr...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
We are a clinical-stage biopharmaceutical company focused on improving the lives o...
We are a clinical-stage biopharmaceutical compa...
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel pr...
Novavax, Inc. is a clinical-stage vaccine compa...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
Join the National Investor Network and get the latest information with your interests in mind.